DXB 8.18% 50.5¢ dimerix limited

DMX-200 for FSGS has orphan drug status which comes with a...

  1. 4,196 Posts.
    lightbulb Created with Sketch. 786
    DMX-200 for FSGS has orphan drug status which comes with a streamlined trial process that is compressed and therefore faster and cheaper, and well within Dimerix's capability to run. DMX-200 for DKD on the other hand will require a much longer and larger trial process that will take years and considerable expense to complete.

    So the rationale would be for Dimerix to do the FSGS trials in-house without having to share any eventual revenue with a partner. This could be funded by further (modest) capital raises, or better still with upfront fees obtained from a Big Pharma partner who takes on the DKD Phase 3 trial in exchange for a share of future revenue. If the FSGS trial is successful, revenue will flow more quickly and fund future activities (such as DMX-700 development and perhaps dividends to shareholders).
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
50.5¢
Change
-0.045(8.18%)
Mkt cap ! $277.8M
Open High Low Value Volume
56.0¢ 58.0¢ 47.0¢ $5.389M 10.26M

Buyers (Bids)

No. Vol. Price($)
2 207369 50.5¢
 

Sellers (Offers)

Price($) Vol. No.
51.5¢ 66004 2
View Market Depth
Last trade - 16.10pm 23/07/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.